BS_K5802F84
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 1.8396846254927726
- age_years
- 15.134
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.497
- PANCREAS_BETA_CELLS+0.420
- SPERMATOGENESIS+0.347
- BILE_ACID_METABOLISM+0.219
- APICAL_SURFACE+0.181
- MYOGENESIS+0.176
- ESTROGEN_RESPONSE_LATE+0.133
- ESTROGEN_RESPONSE_EARLY+0.100
- KRAS_SIGNALING_UP+0.064
- HEDGEHOG_SIGNALING+0.058
Top 10 suppressed
- MYC_TARGETS_V1-0.657
- MYC_TARGETS_V2-0.635
- UNFOLDED_PROTEIN_RESPONSE-0.590
- DNA_REPAIR-0.580
- E2F_TARGETS-0.574
- G2M_CHECKPOINT-0.536
- OXIDATIVE_PHOSPHORYLATION-0.531
- PROTEIN_SECRETION-0.477
- MTORC1_SIGNALING-0.457
- TGF_BETA_SIGNALING-0.453
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_CQSAJ7BF | DNET | — | 0.982 |
| 2 | BS_92VDQ0NE | Ganglioglioma | — | 0.981 |
| 3 | BS_KPT2WPHW | Ganglioglioma | — | 0.980 |
| 4 | BS_JXNZYGCR | DNET | — | 0.970 |
| 5 | BS_6MY8W3H0 | DNET | — | 0.969 |
| 6 | BS_ZR96A4FH | DNET | — | 0.967 |
| 7 | MNG1280 | — | — | 0.966 |
| 8 | BS_C7N3J4NW | high-grade glioma | — | 0.965 |
| 9 | BS_QF5VVZX5 | Ganglioglioma | — | 0.963 |
| 10 | BS_0T17SY47 | low-grade glioma | — | 0.958 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.497 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.347 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.219 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.181 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.176 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.133 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.064 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.058 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |